BAX · Baxter International Inc.
Price
Snapshot
50 fields · last close| Market Cap | $13.71B |
| P/E | — |
| Float | 515.4M |
| Beta | 0.62 |
| Volatility 30D | 42.3% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 74.5 |
| Price | 25.20 |
| Change | −4.91% |
| Prev Close | 26.50 |
| Open | 26.24 |
| Day Low | 25.87 |
| Day High | 27.09 |
| Avg Vol | 8 |
| Avg $ Vol | $224.0M |
| 52W High | 30.00 |
| 52W Low | 15.73 |
| 52W Pos | 66.4% |
| From High | −16.00% |
| From Low | +60.20% |
| Max DD 1Y | −29.05% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +1.35% |
| SMA 50 | +2.76% |
| SMA 200 | +17.69% |
| RSI (14) | 61.1 |
| Vol 90D | 40.8% |
| Vol 1Y | 42.4% |
| 1Y Range | 16–30 |
| Daily bars | 899 |
| Perf Week | +4.08% |
| Perf Month | +8.78% |
| Perf Quarter | −1.89% |
| Perf Half Y | +56.07% |
| Perf Year | +47.71% |
| Perf YTD | +29.23% |
| Prev Day | −4.91% |
| Clavix | B |
| Debt / Eq | 1.54 |
| Curr Ratio | 2.31 |
| Int Cover | 0.3× |
| FCF Margin | 7.5% |
| Rev Growth | +5.7% |
| Profit | Unprofitable |
| Leverage | High |
| Sector rank | 32 / 49 |
What BAX does
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States.
The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories.
The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services.
Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers, and patients at home under physician supervision.
The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers.
It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand.
Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Clavix risk grade
regraded every trading dayBAX grades B, 74.5 of 100. Steadiest on Macro Resilience (66), most exposed on News Sentiment (51, mixed). 0 of the 4 weighted dimensions sit above the Health Care median. Ranks 32 of 49 in Health Care by Clavix score.
How rough the ride is
| BAX | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.62 | 0.79 |
| 30-day realized volatilityannualized, from daily closes | 42.3% | 36.1% |
| Max drawdown, past yearworst peak-to-trough fall | −29.1% | — |
| Typical daily movemedian absolute daily change | 1.60% | — |
| Days beyond ±3%of the last 252 sessions | 57 (23%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| BAX | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.62 | 0.79 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 51% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| BAX | |
|---|---|
| 1 week | +4.1% |
| 1 month | +8.8% |
| Year to date | +29.2% |
| 1 year | +47.7% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| BAX | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 31 Aug |
| Average score0 most bearish, 100 most bullish | 57 |
| Bullish · bearisharticles above 60 · below 40 | 17 · 10 |
| Directionarticles whose tone is improving vs worsening | 17 ↑ 10 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| BAX | |
|---|---|
| Revenue growthyear over year | +5.7% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openBaxter International reported quarterly earnings per share of $0.58, beating the consensus estimate of $0.52 by $0.06. The company had a positive 16.48% return on equity but a negative 6.23% net margin; no revenue figure was included in the excerpt.
Baxter reported third-quarter 2026 revenue of $2.98 billion, up 5% from a year earlier and ahead of the $2.91 billion analysts expected, while adjusted profit, a company-reported measure excluding certain costs or gains, was $0.58 per share versus $0.52 expected. It raised its full-year adjusted profit forecast to $2.10 per share at the middle of its range, but the market reacted negatively as discontinued injectable cephalosporin products and continuing supply-chain problems tempered enthusiasm for the beat.
Baxter International declared a quarterly dividend of $0.01 per share for shareholders of record on November 27, payable January 4. The dividend equals $0.04 per share annualized and a stated yield of 0.2%, with November 27 also listed as the ex-dividend date.
Baxter shares fell more than 4%. No specific catalyst was identified.though revenue grew. The headline also cited reduced odds around third-quarter performance but did not specify the measure.
Baxter International reported third-quarter sales and earnings adjusted for certain items above expectations and raised its full-year 2026 outlook. The company attributed the results to broad-based portfolio growth, improving execution and strong free cash flow generation.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| BTSG | Brightspring Health Services Inc | B | $13.89B | 37.97 | 1.79 | Compare |
| GKOS | Glaukos Corporation | C+ | $14.60B | — | 0.67 | Compare |
| PEN | Penumbra, Inc. | A+ | $12.71B | 79.35 | 0.65 | Compare |
| SOLV | Solventum Corporation | B+ | $15.21B | 10.05 | 0.76 | Compare |
| COO | The Cooper Companies, Inc. | B | $12.25B | 20.28 | 0.79 | Compare |
| DVA | DaVita Inc | B | $12.12B | 12.75 | 0.82 | Compare |
| MOH | Molina Healthcare Inc | B | $11.82B | 22.99 | 0.69 | Compare |
| ALGN | Align Technology, Inc. | B | $11.71B | 27.75 | 1.72 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.